2016 ADX
2016 ADX Banner

Cambridge Healthtech Institute’s Inaugural
Circulating Tumor Cells
Current Challenges and New Directions for Liquid Biopsy
August 23-24, 2016 | Grand Hyatt Hotel | Washington, DC

Circulating Tumor Cells enable monitoring and diagnosis of disease, however, proof of clinical validity and utility holds this diagnostic tool back from routine use. There is still a need for more predictive and prognostic tools, a clearer understanding of the biology of these cells, and universal standards. Cambridge Healthtech Institute’s Inaugural Circulating Tumor Cells conference will address current challenges and new directions as well as provide solutions and steps forward. Particular focus will be given to addressing tumor heterogeneity and determining relevant cells for treatment decisions. Experts will also discuss the viability of early disease detection along with the need for increased sensitivity and tools to correlate mutations with disease.

The meeting will cover a range of topics including:

NEW AND INTERESTING BIOMARKERS

  • cfmiRNA
  • Exosomes
  • Extracellular RNA
  • Defining the best markers
  • Getting FDA approval

MOVING TOWARDS EARLY DETECTION

  • Methylation-based biomarkers
  • Can platforms reach this threshold?
    • Detection at low levels and increasing sensitivity
  • Mutation correlation with disease

MOVING BEYOND ENUMERATION: PREDICTIVE AND PHARMACODYNAMIC BIOMARKERS

  • Therapy selection
  • Treatment monitoring

UNDERSTANDING HETEROGENIETY – WHICH CELLS REALLY MATTER?

  • Universal standards and isolation methods
  • Which cells should we measure and use to inform treatment decisions?

VALIDATING FOR CLINICAL USE

  • Addressing clinical utility on a disease basis
  • Which applications are more likely to succeed?

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality conference program.

If you are interested in presenting, please click here. Replies to proposals can take up to 8-12 weeks. We will notify you once the agenda has been finalized.

Deadline for submission is February 5, 2016.

We welcome your comments, suggestions and speaker suggestions as we shape the 2016 program.

Sincerely,

Samantha

For more details on the conference, please contact:
Samantha Drinkwater
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: sdrinkwater@healthtech.com

For exhibit & sponsorship opportunities, please contact:
Joseph Vacca, M.Sc.
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com


2015 Brochure

2015-Next-Generation-Diagnostics-Summit-Brochure-Thumb


Premier Sponsor 

Precision for Medicine 

View All Sponsors

View Media Partners

Media Gallery Thumb

Related Products

Fourth International Molecular Diagnostics Europe
 
MDX_Logo_150x150